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Background: The ability of inflammatory markers to predict disability in later life has received 
growing attention. However, the current evidence came predominantly from Caucasians and 
the role of genomic ancestry has not been investigated.  
Objective: We investigated the prognostic value of multiple citokynes and chemokines for 
incident disability in admixed older Brazilians and whether genomic African and Native 
American ancestry affects the association. 
Design: Population-based longitudinal study. 
Setting: The Bambui-Epigen (Brazil) Cohort Study of Aging. 
Subjects: 1,171 males and females aged 60 years over 15-year of follow-up. 
Methods: Outcome examined was incident activity of daily living (ADL) disability assessed 
annually (10,039 measures were performed). Serum levels of citokynes (IL6, IL12, TNF, IL10, 
and IL1β) and chemokines (CCL2, CCL5, CXCL8, CXCL9 and CXCL10) were measured at 
baseline. We used 370,539 Single Nucleotide Polymorphisms (SNPs) to estimate each 
individual genomic ancestry proportions. Potential confounding variables included a wide 
range of socio-demographic variables and health indicators. Statistical analyses were based on 
competing risk framework. 
Results: The incidence rate of disability was 57.9 per 1,000 person-years. IL6 level at the 
highest quartile showed an independent association with ADL disability (SRH = 1.32; 95% CI: 
1.03, 1.70). Other inflammatory markers showed no statistically significant associations with 
the outcome. Neither genomic African nor Native American ancestry had an effect modifier 
on the associations (P for interaction >0.05 for all). 
Conclusion: Among multi-inflammatory markers, only IL6 had the potential to identify people 
at increased risk of ADL disability, independently of ethno-racial background. 
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Inflammatory markers have been postulated as a tool to identify people at increased risk of 
disability. 
  
The role of genome-based ancestry on the ability of inflammatory markers to predict disability 
is unknown. 
  
We examined whether genome African and Native American ancestries affect the association 
between inflammatory markers and incident disability in a large cohort of older Brazilian 
adults. 
  
Elevated levels of Interleukin-6 were associated with increased risk of disability, independently 
of genome-based ethno-racial background. 
  





Disability in later life is a public health concern worldwide due to increase in demand and cost 
of long-term care [1]. Identifying predictors of disability can potentially contribute not only to 
a better understanding of underlying mechanisms, but also to targeting vulnerable groups for 
timely prevention. Given that there is evidence linking inflammation to the process of ageing 
and age-related diseases, the ability of inflammatory markers to predict disability in old age 
has received growing attention [2]. 
Cytokines and chemokines are important players in the immune responses [2]. There is 
considerable evidence showing that elevated baseline levels of Interleukin-6 (IL6), a pro-
inflammatory cytokine, has a prognostic value for activities of daily living (ADL) disability or 
impairment in mobility [3–5], muscle strength loss [6–10] and sarcopenia [11] in short and 
medium terms (up to 5 years). The prognostic value of IL6 for long-term physical functioning 
is unknown. In the MacArthur Studies of Sucessful Aging, baseline IL6 level did not predict 
physical functioning performance 7 years later [12]. Studies examining the prognostic value of 
other cytokines and chemokines for physical functioning are still scarse and have reported 
inconsistent results [4, 7, 5].  
The above mentioned evidence came predominantly from Caucasians [2–12]. To the best of 
our knowledge, no previous study has specifically examined the influence of genetic ancestry 
on those associations. Brazil, the largest Latin American country, offers a valuable opportunity 
to explore this issue. The Brazilian population originates from African, European and Native 
American ancestral roots [13]. The absence of legal segregation and other factors contributed 
to an emergence of a highly admixed population [14]. 
We used 15-year follow-up data from the Bambui-Epigen study [15], the longest running 
cohort study of aging in Brazil, with two main objectives: (1) to examine the association 
between multiple inflammatory markers and long term ADL disability; and (2) to investiagate 
whether genomic African and Native American ancestry levels affects the ability of those 
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biomarkers to predict the outcome. 
 
2. Methods 
2.1 Study Population 
The Bambui cohort study of aging is ongoing in Bambuí, a city of approximately 15,000 
inhabitants in Southeast Brazil. From an ethno-racial perspective, the cohort population 
consists of an admixture of African (10%), Native American (5%), and European (85%) 
genomic ancestries, in similar proportions to that estimated for the Brazilian population, 
excluding the Amazon region [14]. Detailed information on this cohort can be found elsewhere 
[15]. Briefly, the population eligible for the cohort consisted of all residents aged 60 years and 
older on the 1st of January 1997 (92% of the 1,742 inhabitants in this age group participated). 
Annually, from 1997 to 2011, cohort members underwent subsequent annual follow-up by 
face-to-face interview. Blood collection and other procedures for the current analysis where 
performed at the baseline survey. Deaths occurring from study enrollment to December 31, 
2011, were considered in this analysis. Deaths were reported by next of kin during the annual 
follow-up interview and were ascertained through the Brazilian mortality information system. 
Death certificates were obtained for 95.5% of all deceased participants. Cohort members with 
an ADL disability at baseline (n = 171) were excluded from the current analysis (see bellow). 
 
2.2 Activity of daily living disability 
Annually, from 1997 to 2011, physical functioning was measured as self-reported limitations 
in the following basic ADL: dressing, walking across a room, bathing or showering, eating, 
getting in or out of bed, using the toilet. The questions had four possible answers: no difficulty, 
some difficulty, great difficulty and unable to perform. Onset of disability was considered when 
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a participant reported, for the first time, great difficulty or unability to perform one or more 
tasks. 
 
2.3 Inflammatory markers (cytokines and chemokines) 
Blood samples for measurement of cytokines and chemokines were collected at the baseline 
survey in early morning. The Cytometric bread array assay (CBA immunoassay kit; Becton 
Dickinson, California) was used for the quantitative determination of the serum cytokines 
(Human Inflammatory kit) and chemokines (Human Chemokines kit) levels according to the 
instructions of the manufacturer. Data was acquired using a FACSVerse flow cytometer 
(Becton Dickinson, California). BD FCAP Array 3.0 software (Becton Dickinson, California) 
was used for sample analysis. The coefficients of variation intra and inter-assays were 5-10% 
and 7-12%, respectively. Based on their distributions, IL6, CXCL8, CCL2, CXCL9, CCL5 and 
CXCL10 were log-transformed and considered as continuous variables in our analysis. IL1β, 
IL10, IL-12 and TNF showed very low detectable levels and were considered as dichotomous 
variables. 
 
2.4 Genetic and ancestry analyses 
Cohort participants were genotyped with the Omni 2.5M array (Illumina, California) [13]. 
Ancestry inference was performed by using the model-based method [16]. We used 370,539 
SNPs to estimate each individual African, European and Native American tri-hybrid ancestry 
proportions, based on public datasets parental populations. We used the matrix of kinship 
coefficients and a network-based approach to identify families, and identified them as 
categorical variables for the association tests described below. Pairs of individuals were 
considered as related if they had a kinship coefficient >0.1 (first and second-degree relatives). 




Covariates comprised baseline socio-demographic characteristics (age, sex, education and 
household income), lifestyle (smoking, alcohol consumption and physical activity), body mass 
index and health conditions. We categorized schooling into <4 years, 4-7 and 8 years. 
Monthly household income per capita was divided into tertiles (<USD 90.00 is the lowest 
tertile). Current smokers were participants who had smoked at least 100 cigarettes during their 
lifetime and who still smoke. Leisure-time physical activity was defined as activity of any 
intensity for 20-30 minutes in the previous 3 months, and categorized into at 3 times a week, 
<3 times a week and never. Alcohol consumption was defined by consumption of 14 doses per 
week in previous 12 months. Body mass index was categorized into <18.5, 18.6-24.9 and 24 
kg/m2. Health conditions considered were: hypertension (systolic blood pressure 140 mmHg 
or diastolic blood pressure 90 mmHg and/or treatment); diabetes (fasting blood glucose 126 
mg/dL and/or treatment); arthritis (previous medical diagnosis of any joint condition); coronary 
heart disease (medical diagnosis of myocardial infartion or angina pectoris as assessed by the 
Rose’s questionnaire); intermitent claudication (Rose’s questionnaire), stroke (medical 
diagnosis), fasting high non-HDL cholesterol (130 mg/dL); heart failure (plasma B-type 
natriuretic peptide level >100 pg/mL); anaemia (hemoglobin <13g/dL for men and <12g/dL 
for women), depressive symptoms (defined by a 12-item version of the General Health 
Questionnaire score 5 [17]); cognitive impairment (defined by a Mini-Mental State 
Examination score <22 - below the 25th percentile- or by the need for a proxy interview- 87 
participants). Based on the above mentioned health conditions (all as dichotomous variables) 
we used principal component analysis [18] to create a morbidity score that ranged from - to 
+ (higher scores indicated worse health). Scores were divided into quartiles. 
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2.6 Statistical analysis 
We used competing-risks regression [19] to estimate the multivariate subhazard ratios (SHR) 
to model 15-year survival-time disability data. In order to consider death that could be related 
to disability, we used the date of death as a competing risk event. All regression models using 
genomic measures included a clustered (family) robust variance term to avoid potential bias 
resulting from analysis of individuals who were related (807 participants were first- and 
second-degree relatives). 
First, we examined the association between inflammatory markers with incident ADL disabilit, 
by estimating sub hazard ratios (SRH) adjusted for socio-demographic, lifestyle, body mass 
index and health conditions (morbidity score). Then we added genomic ancestry variables to 
the previous models. Furthermore, we examined separately the statistical significance of 
multiplicative interactions between the inflammatory marker and genomic African and Native 
American ancestry on the outcome, controlling for all the above mentioned covariates. A 
statistically significant association was defined by a P value <0.05 in the log-likelihood test. 
An additional analysis was performed to examine the association between baseline quartiles of 
IL6 serum levels and incident ADL disability. In this analysis we also examined the possibility 
of reverse causation by excluding those participants whose disability onsets occurred within 
12 months. Furhter, we implemented fully adjusted competing-risks regression models to 
estimate cumulative incidence rates for disability by year, according with baseline IL6 levels 
in quartiles and plotted the results. Because we did not have enough power to stratify the 
analysis by gender, men and women were pooled and sex was considered as a covariate in our 






Our analysis was based on 1,171 participants who had no ADL disability at baseline and had 
complete information for all other study variables. During the study period, 383 cohort 
participants died, 581 evolved to disability and 104 were lost to follow-up. Along the 15-year 
follow-up, 10,039 measures of ADL were made. The incidence rate of disability was 57.9 per 
1,000 person-years. The mean age was 68.6 years (range 60 to 95) and 61.0% were women. 




Table 1. Baseline socio-demographic and health characteristics of study participants. The Bambui 




(n = 1,117) 
Socio-demographic   
Age in years, mean (SD) 68.6 (6.7) 
Women  61.0 
Monthly Family income per capita <USD 90.00 28.5 
Lifestyle  
Current smoking 17.1 
Alcohol consumptions in previous 12 months (>14 doses per week) 2.9 
Physical activities during leisure time in previous 3 months (<3 times a week)  85.2 
Body mass index in kg/m2, mean (SD) 24.9 (4.7) 
Health conditions  
Hypertension (SBP 140 e/or DBP 90 mmHg and/or treatment)  60.4 
Diabetes (fasting blood glucose >126 mg/dL and/or treatment) 14.3 
Arthritis (medical diagnosis of any joint condition)   24.9 
Coronary heart disease (medical diagnosis of myocardial infarction or 
coronary heart disease as assessed by the Rose’s questionnaire) 
12.6 
 Intermittent claudication (Rose’s questionnaire)  2.5 
Stroke (medical diagnosis) 2.8 
Non-HDL cholesterol 130 mg/dL 89.4 
Heart failure (B-type natriuretic peptide >100 pg/mL) 39.1 
Anemia (hemoglobin <13g/dL for men and <12g/dL for women) 3.4 
Depressive symptoms (General Health Questionnaire score 5, range 0-12) 33.6 
Possible cognitive impairment (MMSE score <19, range 0-26, or need for a 
proxy) 
21.7 
Genomic ancestry individual proportions   
African, median (p25, p75) 9.6 (4.7, 17.0)  
Native American, median  (p25, p75) 5.2 (2.7, 8.2) 
European, median (p25, p75) 84.3 (74.6, 91.5) 
Biomarker plasma levels (pg/mL)  
IL6 , median (p25, p75) 1.0 (0.4, 2.0) 
CXCL8, median (p25, p75) 5.1 (2.9, 9.4) 
CCL2, median (p25, p75)  38.7 (25.4, 56.2) 
CXCL9, median (p25, p75) 2,228 (1,230, 3,913) 
CCL5, median (p25, p75)  870 (565, 1,661) 
CXCL10, median (p25, p75) 2,970 (1,978, 4,670) 
IL10 (14.0 pg/mL)b 24.9 
IL12 ( 0.01 pg/mL)b 7.7 
TNF (0.01 pg/mL)b 16.9 
IL1β (0.01 pg/mL)b 21.4 
aData are presented as percentage, except when specified. 
bLowest detectable level. 
SD = standard deviation; MMSE = Mini-Mental State Examination; SBP = systolic blood pressure; 




As shown in Table 2, IL6 baseline serum level showed a positive statistically significant 
association with ADL disability in a model adjusted for socio-demographic, lifestyle, body 
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mass index and morbidity score (SHR = 1.07; 95%CI: 1.01–1.13). Further adjustments for 
genomic African and Native American ancestry had no impact on the above mentioned 
estimates. Other biomarkers showed no statistically significant association with the outcome. 
Additionally, we found no evidence of statistically significant interactions affecting the ability 
of any biomarker to predict ADL disability neither for African nor for Native American 
ancestry (P for interaction >0.05 for all). 
 
 
Table 2. Sub hazard ratios of 15-year incident activity of daily living disability, according with 
baseline multi-inflammatory serum levels. The Bambui Cohort Study of Aging (1997-2011) 
 
Biomarkers 
Model adjusted for 
sociodemographic, 
lifestyle, body mass 
index and 
morbidity score 
Model adjusted for 
sociodemographic, 
lifestyle, body mass 
index, morbidity score, 
African ancestry 
proportion and cluster in 
family 
Model adjusted for 
sociodemographic, lifestyle, 
body mass index, morbidity 
score, African ancestry and 
Native American proportion 
(continuous) and cluster in 
family 
SRH (95%CI) SRH (95%CI) SRH (95%CI) P-valuea 
IL6b 1.07 (1.01–1.13) 1.07 (1.01–1.13) 1.07 (1.01–1.13) 0.021 
CXCL8b 1.05 (0.98–1.11) 1.04 (0.98–1.11) 1.04 (0.98–1.11) 0.224 
CCL2b 0.99 (0.88–1.12) 0.98 (0.87–1.11) 0.99 (0.88–1.11) 0.859 
CXCL9b 1.01 (0.99–1.05) 1.02 (0.99–1.05) 1.02 (0.99–1.05) 0.293 
CCL5b 0.99 (0.92–1.08) 0.99 (0.92–1.08) 0.99 (0.92–1.08) 0.946 
CXCL10b 0.99 (0.97–1.01) 0.99 (0.97–1.01) 0.99 (0.97–1.01) 0.415 
IL10c 0.91 (0.74–1.16) 0.92 (0.75–1.13) 0.92 (0.74–1.13) 0.407 
IL12d 1.27 (0.96–1.68) 1.27 (0.99–1.72) 1.26 (0.93–1.05) 0.141 
TNFd 1.12 (0.90–1.41) 1.13 (0.90–1.40) 1.12 (0.90–1.39) 0.323 
IL1βd 0.89 (0.72–1.10) 0.89 (0.73–1.10) 0.90 (0.73–1.11) 0.303 
SHR (95%CI) = sub hazard ratios and 95% confidence intervals, estimated by competing-risks 
regression. 
aLog-likelihood test. 
bLog-transformed values (continuous). 
c14.0 pg/mL vs. not detectable. 





IL6 level at the highest quartile showed statistically significant association with ADL disability 
in the analysis adjusted for socio-demographic, lifestyle and health variables (SRH = 1.34; 
95%CI: 1.04–1.71) (Table 3). Again, the addition of genomic ancestry variables to the previous 
models had no impact on the predictive value of IL6 levels for ADL disability. The exclusion 
of onsets prior to 12 months slightly increased the SHR values, and the graded nature of the 
association became more evident with SRH (95% CI) equal to 1.33 (0.98–1.81), 1.40 (1.04–
1.88) and 1.48 (1.09–2.01) for those at the 2nd, 3rd and the highest relative to the lowest quartile. 
Figure 1 shows the cumulative probability of ADL disability by year, according with quartiles 
of baseline IL6. The clearly separated lines between the highest and the lowest quartile support 
the associaton between the biomarker level and the risk of ADL disability showed in Table 3. 
 
 
Table 3. Incidence rates and sub hazard ratios (95% confidence interval) of 15-year incident activity 











lifestyle, body mass 
index and 
morbidity score 
SHR (95%CI) adjusted for 
sociodemographic, lifestyle, body mass 
index, morbidity score, African and Native 
American ancestry proportions (continuous) 
and cluster in family 
All participants 
Excluding onsets prior 
to 12 months 
   Lowest 128 (39.0) 1.0 1.0 1.0 
   2nd 143 (55.1) 1.17 (0.91–1.50) 1.18 (0.92–1.51) 1.33 (0.98–1.81) 
   3rd 156 (69.6) 1.20 (0.94–1.54) 1.19 (0.95–1.53) 1.40 (1.04–1.88)b 
   Highest 154 (79.9) 1.34 (1.04–1.71)b 1.39 (1.05–1.72)b 1.48 (1.09–2.01)b 
SHR (95%CI) = sub hazard ratios and 95% confidence intervals, estimated by competing-risks 
regression. 
aLowest: 0.5; 2nd: 0.5-1.1; 3rd: 1.2-2.1; highest: 2.2 pg/mL. 




Figure 1. Fully adjusted cumulative incidence of disability over 15 years by baseline serum levels of 




Estimated by competing risk regression, and adjusted for socio-demographic, lifestyle, body mass 




Our major finding is that elevated IL6 serum levels predicted very long term incident ADL 
disability. The observed association persisted after careful controlling for a wide range of 
covariates, and suggests graded effect. Because this association remained after excluding 
onsets prior to 12 months, it appears not to be explained by reverse causation, that is, a situation 
in which the outcome precedes and causes the exposure instead of the other way around [20]. 
Notably, the individual proportion of genomic African and Native American ancestry did not 
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affect the predictive value of this biomarker for the outcome. 
The association between IL6 levels with ADL disability is in agreement with a number of 
previous studies conducted in the USA and Europe [2–11]. Two novel findings are that (i) IL6 
predicts ADL disability in very long term in an admixed population and that (ii) ancestry 
background does not play a role on this association. Another issue is the cut off value of the 
marker. IL6 cut offs of 2.50 pg/mL [3], 2.98 pg/mL [5] and 3.1 or 3.8 pg/mL [10] have been 
proposed to discriminate persons at risk and those not at risk for disability. Our results showed 
that persons with IL6 level higher than 2.2 pg/mL were at increased risk. 
The exact mechanism linking increased IL6 level to disability is unclear. The catabolic effect 
of IL6 on muscle has been postulated [6, 7, 11]. However, because IL6 is associated with 
increased risk of chronic diseases that, in turn, predispose to disability, there is a debate about 
whether IL6 is a direct cause of physical decline or simply sumarize the burden of illness in 
older adults [2]. Our results indicate that IL6 predicts ADL disability, independently of several 
health and health-related measures, but we were not able to capture changes over time. 
Therefore, the key issue is to disentangle the complex pathway linking IL6 to disability, which 
was not possible in our analysis. 
There are only few studies examining the association between other cytokines and chemokines 
with physical decline. Two earlier reports, involving around 2,000 participants from the Health, 
Aging and Body Composition studies showed an association between baseline TNFα with 30-
months incident mobility limitation [4] and with a 5-year decline in grip strenght in men (but 
not in women) [7]. A more recent study, involving 303 participants of the Belfrail Study in 
Belgium, examined the association between a large battery of cytokines and chemokines with 
1.66-year global functioning decline. Except for IL6, no other biomarker had the potential to 
identify persons at increased risk [5]. Our results, based on a larger number of participants and 
a longer follow-up period, is in agreement with the latter, that is, among a large battery of 
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cytokines and chemokines, only IL6 was found to be statistically significantly associated with 
incident ADL disability. 
Strengths of the present study include its well-defined community-based sample followed for 
a long period. Our study also incorporated a robust set of health and health-related measures 
that could confound the association between the inflammatory markers and onset of disability. 
Another important strength was the use of genome measures of ancestry, instead of ethno-racial 
self-classification, which is prone to misclassification, particularly in admixed populations 
[14]. A limitation in this analysis is inherent to longitudinal studies of ageing. Older adults are 
at increased risk of death, which in turn might lead to differential censoring. As an attempt to 
overcome this limitation, we used competing risk framework in our analysis, considering the 
data of death as informative censoring. In our initial exploratory analysis of the association 
between multiple citokynes and chemokines with the outcome, we did not adjust for multiple 
testing – which could lead to false positive results. However, the association between IL-6 with 
incident ADL disability was confirmed in subsequent analysis based on the quartile distribution 
of the biomarker level and, also, in an analysis restrict to onsets after 2 years. Therefore, it is 
unlekly that those are false positive results. In addition, changes over time in exposure status 
and ADL trajectories were not investigated. This limitation, however, do not preclude our 
conclusion that, despite eventual unmeasured changes over time, baseline elevated level of IL6 
is an independent predictor for very long-term ADL disability. 
In summary, our findings showed that in a cohort of admixed older Brazilian adults, only IL6 
has the potential to identify persons at increased risk of future ADL disability, independently 
of ethnoracial background. 
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